Arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in: adults 60 years of age and older; adults 50 through 59 years of age who are at increased risk for RSV disease.
The use of this vaccine should be in accordance with official recommendations.